Michael F. Walsh

Memorial Sloan Kettering Cancer Center

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index50

i10-index107

Publications314

Citations13,771

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 37

The <scp>WHO</scp> Classification of Genetic Tumour Syndromes: Considerations for Genetics
Clinical Genetics · 2026-06-16
Expanded germline genetic testing of patients with hematologic malignancies to identify high proportion with hereditary cancer predisposition.
Journal of Clinical Oncology · 2026-05-27
Prevalence, tumor characteristics, and clinical impact of <i>LZTR1</i> pathogenic variants in a large, pan-cancer cohort.
Journal of Clinical Oncology · 2026-05-27
The <scp>WHO</scp> Classification of Genetic Tumour Syndromes: Considerations for histopathology
Histopathology · 2026-03-19
De Novo Germline <i>L858R EGFR</i> Variants and Generalized Acanthosis Nigricans
JAMA Dermatology · 2026-01-14
Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the <scp> <i>RTEL1</i> R1264H </scp> Founder Variant
American Journal of Medical Genetics Part A · 2025-12-22
Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Table 6, Supplemental Table 7, Supplemental Figure 1, and Supplemental Figure 2 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025-12-17
Data from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025-12-17
Supplemental Table 5 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025-12-17
Supplemental Materials and Methods from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025-12-17
Supplemental Table 4 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations
2025-12-17
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025-11-26
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025-11-26
Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025-11-26
Figure S4 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
2025-11-25
Figure S3 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
2025-11-25
Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
2025-11-25
Figure S7 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
2025-11-25
Figure S2 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
2025-11-25
Figure S1 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
2025-11-25

Open author page on OpenAlex →